Non Subscriber: Buy This Issue

Hepatitis C Treatment: Gone Viral

Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for the issue, return to this Introduction page and click the "Take the Test" button. The Introduction page will remain open after you open this issue.
You may need to re-size or close the issue in order to see the Introduction page.

Overview

Hepatitis C virus (HCV) remains a major public health concern. HCV, the most common blood borne infection in the US, is estimated to affect over 4 million Americans (about 1-2% of the population). Worldwide, over 170 million people are infected. Most Americans with HCV infection acquired it in the 1970s and 1980s, before the virus was identified. Although the rate of new infections declined between 1989-2011, there has been a recent increase in new infections since 2013. Unfortunately, there is no effective HCV vaccine at this time. The majority of people with acute HCV infection develop chronic infection; only 15-25% clear the infection spontaneously. Most individuals with chronic HCV infection are asymptomatic; some may experience nonspecific symptoms such as fatigue. Among those who were infected 10-30 years ago, about 50% remain undiagnosed. Consequently, a high percentage of infected people are unaware that they have HCV, can transmit it to others, and do not seek medical help or treatment.

HCV causes liver inflammation, resulting in advanced scarring (cirrhosis) in 10 to 20% of those infected. Chronic HCV infection is a leading cause of cirrhosis, liver cancer, and endstage liver disease requiring transplantation. In 2012, over 22,900 deaths related to liver cancer occurred in the US. From 1999 to 2013, the largest increase in liver cancer and deaths occurred in individuals born during 1945 through 1965 compared to other birth-year groups. Early detection and appropriate HCV antiviral treatment can reduce the risk of progressive disease and death...

Details

Publication Date: 10/23/2016
Expiration Date: 10/23/2019
CE Credit: 1.5 (0.15 CEU)
Type of Activity: Knowledge-based

This program was developed by The Rx Consultant and published by Continuing Education Network, Inc. The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased, balanced information to health care practitioners.

Programs developed by The Rx Consultant are written by health care providers with expertise in the topic area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure that every program presents information that is current, accurate, relevant to "real world" health care providers, and written in an easy reading, "plain English" style.

Authors

Helen Yee, PharmD, is Associate Clinical Professor of Pharmacy, School of Pharmacy, University of California, San Francisco; Adjunct Faculty, School of Pharmacy, University of the Pacific, Stockton, CA; and Clinical Pharmacy Specialist, Department of Veterans Affairs Medical Center, San Francisco; National Hepatitis C Resource Center, Department of Veterans Affairs.

Disclosure Statement

Dr. Yee reports no financial relationship with the manufacturer(s) or provider(s) of any commercial product(s) 1 or service(s) that appears in this issue.

Target Audience

This accredited program is targeted to pharmacists and nurses.

Goals & Objectives

At the conclusion of this program, participants will be able to:

    1. Describe the prevalence and general course of HCV disease, risk factors, and factors that may worsen HCV disease.
    2. Outline general antiviral treatment considerations, including social factors, HCV genotype, disease severity, and coexisting medical conditions.
    3. Describe the DAA regimens for HCV genotypes 1, 2, and 3, including dosing, duration, indications, contraindications, and potential drug-drug interactions.
    4. List common side effects of DAA agents and management strategies. Counsel patients on the importance of adherence.

Accreditation Statements

The Rx Consultant is a publication of Continuing Education Network, Inc.

Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education as a provider of continuing pharmacy education.

Continuing Education Network is approved by the California Board of Registered Nursing, Provider Number CEP 13118. Programs approved by CA BRN are accepted by most State Boards of Nursing.

ACPE Universal Activity Number: 0428-0000-16-009-H01-P


Exam & Credit Statement Procedures

Upon successful completion of this program and the post test (70%), 1.5 hours of continuing education credit will be awarded. To receive credit and your exam score, please complete the exam questions and program evaluation.

Editorial and Review Board

Chief Editor and CE Administrator


Terry M. Baker, PharmD

Managing Editor


Tracy Farnen, PharmD

Associate Editors


James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Kaiser Permanente
Oakland, CA

Associate Clinical Professor
School of Pharmacy
University of California San Francisco
San Francisco, CA

Richard Ron Finley, B.S. Pharm.,R.Ph.
Clinical Pharmacist (volunteer faculty)
University of California, San Francisco (UCSF) Memory and Aging Center
Lecturer (Emeritus) UCSF, Department of Clinical Pharmacy
Health Sciences Clinical Professor, UCSF School of Pharmacy
San Francisco, CA

Consultant Pharmacist
Ray Dolby Brain Health Center, Sutter Health/CPMC
San Francisco, CA

Consult Pharmacist Aging and Adult Health Services
San Francisco Health Department
San Francisco, CA

Julio R. Lopez, PharmD, FCSHP
Chief of Pharmacy Service
VA Northern California Health Care System

Adjunct Clinical Professor
College of Pharmacy
Touro University
Vallejo, CA

Assistant Clinical Professor
School of Pharmacy
University of California, San Francisco
San Francisco, CA Adjunct Professor
Thomas J. Long School of Pharmacy
University of the Pacific
Stockton, CA

Visiting Associate Professor and Lecturer
Nursing School
Samuel Merritt University
Oakland, CA

Pamela Mausner, MD

Helen Berlie, Pharm.D. CDE, BCACP
Clinical Assistant Professor, Pharmacy Practice
Wayne State University
Detroit, MI

Ambulatory Care Specialist - Diabetes
Health Centers Detroit Medical Group
Detroit, MI

Senior Editorial Advisor


Gerard Hatheway, PharmD, PhD

Editorial Advisors


Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Angie S. Graham, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD

Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners


Emily K.
Meuleman, RN, C, MS

About the Rx Consultant

The Rx Consultant is a monthly publication dedicated to providing health care professionals with the information they need to educate patients about drugs and manage drug therapy. The reader is responsible for confirming the information presented here and interpreting it in relation to each patient's specific situation before utilizing the information.

Technical Specifications

Hardware requirements

Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.

Software requirements

Browser that supports TLS 1.1 + and PDF files.

This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.

Adobe Acrobat Reader is recommended, and is required for some browsers.

Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.

Internet Connectivity

Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)

Contact Us

Exam Processing Inquiries

The Rx Consultant
rxmail@rxconsultant.com
1-800-798-3353

Educational Content Inquiries

The Rx Consultant
editor@rxconsultant.com
1-800-798-3353

Non Subscriber: Buy This Issue